

Endo GUC Trust

Financial Statements
as of and for the Quarter Ended March 31, 2026
(Unaudited)

Endo GUC Trust

Unaudited Statement of Net Assets in Liquidation as of December 31, 2025 and March 31, 2026		
(Thousands)		
Assets	December 31, 2025	March 31, 2026
Cash and cash equivalents	\$9,994	\$9,603
Total assets	\$9,994	\$9,603
Liabilities	\$0	\$0
Net assets in liquidation	\$9,994	\$9,603

Endo GUC Trust

Unaudited Statement of Changes in Net Assets in Liquidation	
For the Period December 31, 2025 to March 31, 2026	
(Thousands)	
Receipts	
Proceeds of litigation funding (prepaid forward sale receipts) (1)	\$0
Litigation settlements received	\$0
Interest received	\$62
Total receipts (2)	\$62
Operating Expenses	
Trustee, Trust Oversight Board and Trust professional fees and expenses	\$448
Other operating expenses	\$5
Total operating expenses	\$453
Total increase (decrease) in net assets in liquidation (2)	\$391

(1) Net of transaction costs paid by and deducted by purchasers prior to funding to the Trust, but gross of transaction costs paid or to be paid by the Trust (shown or to be shown in Operating Expenses for the periods in which paid).

(2) Sums may vary due to rounding.

Endo GUC Trust

NOTES TO FINANCIAL STATEMENTS (Unaudited)

1. Description of the Trust

On August 16, 2022, Endo International plc and on August 16, 2022 or certain later dates, certain of Endo International plc's affiliates (collectively, the "Debtors") commenced proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court"). On March 22, 2024, the Bankruptcy Court confirmed the Debtors' *Fourth Amended Joint Chapter 11 Plan of Reorganization* (the "Plan") and on April 23, 2024, the Plan became effective (the "Effective Date").

The Endo GUC Trust (the "Trust") was established pursuant to the Plan on April 11, 2024 as a Delaware statutory trust, of which Matthew Dundon serves as trustee (solely in his capacity as the trustee of the Trust and not in any individual capacity, the "Trustee"). The Trust is presently governed by the Endo GUC Trust Agreement, dated April 23, 2024 (the "GUC Trust Agreement"). The GUC Trust Agreement provides for rights, obligations and means of governance of the Trust as contemplated by the Plan. The GUC Trust Agreement defines certain terms used in these Notes to Financial Statements.

The Trust issued Class A Units to former holders of claims arising under second lien and unsecured notes issued by the Debtors ("Notes"), and Class B Units (together with the Class A Units, the "Units") to former holders of Other General Unsecured Claims against the Debtors. In accordance with the terms of the GUC Trust Agreement, the holders of Units are entitled to receive certain cash distributions from the Trust, the initial distributions of which cash were made in the year ended December 31, 2024 and which are further described below. The Trust also made in the year ended December 31, 2024 cash distributions to certain sub-trusts created for the benefit of former holders of Mesh Claims, Ranitidine Claims, Generic Price Fixing Claims and Reverse Payment Claims (each as defined in the Plan) against the Debtors (collectively, the "Sub-Trusts") and under certain circumstances will be required to, and shall, make additional distributions to the Mesh Claims Sub-Trust in the future. (The Plan and GUC Trust Agreement contemplated possible additional payments to the Ranitidine Claims Sub-Trust, but in the year ended December 31, 2024, the Trustee determined that the conditions for making such payments will not arise.; *see* Note 9).

On the Effective Date and pursuant to the Plan, the Debtors transferred certain causes of action and insurance rights (collectively, the "Causes of Action"), cash and certain other assets to the Trust.

Additional information and documentation concerning the Trust can be found on the Trust's website at www.EndoGUCTrust.com.

2. Certain Interim Accounting Policies

The unaudited Financial Statements (the "Statements") reflect the accounts of the Trust. The Statements have not been prepared in accordance with generally accepted accounting principles; rather they have been prepared using a liquidation basis of accounting, which the Trust considers an appropriate basis of accounting at this time.

Endo GUC Trust

The Statements were prepared using certain accounting policies, most importantly:

- (a) no asset or liability value will be assigned to Causes of Action until and unless a judgment of damages is entered or a settlement definitively agreed, in which case the gross amount of the judgment or settlement will be accrued as an asset and the aggregate amount of contingent legal fees and litigation finance payment obligations, if any, arising from such settlement or judgment if and when funded will be accrued as liabilities;
- (b) the Trustee will not disclose the existence or progress of any mediation (except and solely to the extent the existence or progress of any mediation has become public information), the existence or status of any settlement negotiations, nor its litigation or other strategy concerning the Causes of Action, nor (except and to the extent already disclosed or required by the applicable court or arbitrator) its funding arrangements for the Causes of Action including contingency fee terms and the terms of the Litigation Financing as such term is below defined (see note 7);
- (c) unpaid invoices and unbilled works in progress of Trust professionals will not be accrued as an expense nor realized as liability – note that the exclusion of unpaid invoices from liabilities is a change in interim accounting policies made on the advice of the Trust’s external accounting firm;
- (d) amounts payable or possibly payable to beneficiaries of the Trust will not be realized as liabilities;
- (e) disclosures on a per-Unit basis will be made upon the adoption of definitive accounting policies; and
- (f) the Trustee will not consolidate or report on the finances of the Sub-Trusts.

Each of these interim policies is subject to change.

3. Receipts

During the quarter ended March 31, 2026, the Trust’s receipts consisted of \$0.06 million in interest paid on the Trust’s cash balances.

All the Trust’s cash received during the quarter ended March 31, 2026 was and remained as of March 31, 2026 deposited in insured or collateralized interest-bearing bank accounts, and interest paid upon such deposits is set forth above in the Trust’s Unaudited Statement of Changes in Net Assets in Liquidation. Subject to the requirements of the GUC Trust Agreement, the Trustee may change the deposit and/or investments of the Trust’s liquid assets from time to time.

4. Trustee, Trust Oversight and Trust Professional Fees and Expenses

On April 23, 2024, a five-member Oversight Board was appointed by the Official Committee of Unsecured Creditors of the Debtors. The Oversight Board’s members were upon each of the Effective Date and December 31, 2025: (i) Morton Branzburg (designated in the interests of the

Endo GUC Trust

Debtors' general unsecured non-funded debt creditors), Ephraim Diamond (designated as the Independent Board Member as such officer is defined in the GUC Trust Agreement), and Daniel Golden, Dennis Prieto, and Himanshu Sheth (each designated in the interests of the Debtors' unsecured and second lien bondholders).

During the quarter ended March 31, 2026, the Trust expended \$0.4 million in Trustee, Trust Oversight Board and Trust professional fees and expenses. Legal services in relation to Causes of Action and Litigation Financing (as below defined) accounted for the substantial majority of this expenditure. This figure includes the portion of fixed monthly costs actually paid, totaling \$0.08 million, for the monthly compensation of the Trustee and certain members of the Oversight Board. Dundon Advisers LLC, financial adviser to the Trustee, provides the Trust with office facilities and ministerial services at no charge.

5. Other Expenses

The Trust's other expenses of \$0.005 million in the quarter ended March 31, 2026 consisted of bank fees.

6. Distributions and Payments Required by the Plan

During the quarter ended March 31, 2026, no distributions or payments to beneficiaries of the Trust or providers of the Litigation Financing were required to be made by the Plan or the definitive documents of the Litigation Financing, respectively, and, as the Trust did not elect to make any voluntary distributions or payments, no such distributions or payments were made.

7. Litigation Financing

No disclosable events relating to Litigation Financing occurred in the quarter ended March 31, 2026.

8. Tender and Registration Activities

No tender or registration activities occurred in the quarter ended March 31, 2026.

9. Causes of Action Litigation

Directors and Officers Litigation (*De Silva, et al.*)

During the year ended December 31, 2024, the Trustee filed a complaint in the Bankruptcy Court asserting Causes of Action against certain of the former Debtors' directors and officers captioned *Matthew Dundon, Trustee of the Endo GUC Trust, Plaintiff, v. Rajiv De Silva, Douglas S. Ingram, Arthur J. Higgins, Nancy J. Hutson, Roger H. Kimmel, William P. Montague, Todd B. Sisitsky, Jill D. Smith, William F. Spengler, Paul V. Campanelli, Suketu P. Upadhyay, Karen A. Wallace, Brian Lortie, Antonio R. Pera, Joseph Barbarite, and John Does 1-10* (24-AP-07022).

During the year ended December 31, 2024, the defendants commenced an action in United States District Court for the Southern District of New York ("SDNY District Court") to remove the action from the Bankruptcy Court (24-CV-7464), and the Trust timely opposed this motion.

Endo GUC Trust

On January 6, 2025, the defendants filed with the Bankruptcy Court a motion to dismiss the case. On March 17, 2025, the Trustee filed with the Bankruptcy Court its opposition to the defendants' motions to dismiss. The Trustee submitted a supplemental letter to the Court on April 30, 2025 to which the defendants replied on May 8, 2025.

The motion to dismiss and the motion to withdraw the reference were each fully briefed and, with no party requesting oral argument, were pending decision before its respective court as of March 31, 2026.

McKinsey Litigation (*McKinsey, et al.*)

During the year ended December 31, 2024, the Trustee filed a complaint in the Bankruptcy Court asserting Causes of Action against former strategy consultants to the former Debtors captioned *Matthew Dundon, Trustee of the Endo GUC Trust, Plaintiff v. McKinsey & Company, Inc. and McKinsey & Company, Inc. United States* (24-AP- 07027).

On January 10, 2025, the Trustee filed with the Bankruptcy Court its opposition to McKinsey's motion to dismiss which had been filed in the year ended December 31, 2024. The motion to dismiss was argued on March 6, 2025 in the Bankruptcy Court. The Bankruptcy Court granted in part, and denied in part, the motion to dismiss on September 29, 2025. The Bankruptcy Court's order denied dismissal of the Trustee's expense indemnification claims, which represent a substantial portion of the total damages sought. As of March 31, 2026, the Trustee had determined not to seek an interlocutory appeal of the dismissal of certain counts, and the parties were engaged in the preliminary phases of pretrial discovery. (The Trust reserves the right, if the case is not settled, to appeal the dismissal of the counts in its complaint which were dismissed).

Product Liability Insurance Coverage Litigation (*ACE Property and Casualty Insurance Company, et al.*)

During the year ended December 31, 2024, the Trustee filed a complaint (and thereafter an amended complaint) in the United States District Court for the Eastern District of Pennsylvania (the "Pennsylvania District Court") asserting Causes of Action against certain product liability insurers of the former Debtors captioned *Matthew Dundon, as the Trustee of the Endo General Unsecured Creditors' Trust, Plaintiff, v. ACE Property and Casualty Insurance Company, et al.* (24-CV-04221). The defendants timely filed motions to dismiss and other procedural proceedings, and the Trustee voluntarily dismissed certain of the actions, including all relief sought previously in connection with ranitidine claims.

On January 22, 2025, the Bankruptcy Court denied the leave which certain defendants had sought to proceed against the Trust in Delaware State Court.

In the year ended December 31, 2025, many of the defendants filed summary judgement motions, which the Trustee timely opposed.

Certain additional pleadings in relation to motions for summary judgment were filed on January 30, 2026.

On February 10, 2026, the Court granted in part and denied in part certain of the defendants'

Endo GUC Trust

motions for summary judgment and denied the Trustee's motions for summary judgment. As of March 31, 2026, neither the Trustee nor any of the defendants appealed any portion of these rulings disfavorable to them.

On February 26, 2026, the Trustee moved for summary judgment in relation to certain of its causes of action, to which the adverse parties timely filed an opposition on March 19, 2026. The motion was awaiting further proceedings as of March 31, 2026.

In the quarter ended March 31, 2026, the Trustee and certain defendants engaged in confidential settlement negotiations.

Sponsor Litigation (*TPG Capital, L.P., et al.*)

During the year ended December 31, 2024, the Trustee filed a complaint in the Bankruptcy Court asserting Causes of Action against certain former shareholders of one of the former Debtors captioned *Matthew Dundon, Trustee of the Endo GUC Trust, Plaintiff, v. TPG Capital, L.P., et al.* (24-AP-07030). On November 25, 2024, the defendants filed a motion to dismiss the action. On December 6, 2024, the action was reassigned from Bankruptcy Court Judge James L. Garrity, Jr. to Bankruptcy Court Judge David S. Jones.

On January 31, 2025, the Trustee filed an amended complaint, and filed a corrected version of the amended complaint on February 3, 2025. The defendants timely moved to dismiss the case on April 1, 2025, which the Trustee timely opposed on June 3, 2025 and June 4, 2025. On September 30, 2025, oral arguments were heard on the motion before Bankruptcy Judge David S. Jones. The motion to dismiss was pending decision as of March 31, 2026.

10. Subsequent Developments

The following developments occurred between April 1, 2026 and May 14, 2026, inclusive. This discussion excludes litigation developments which are non-disclosable pursuant to the policies noted above and developments which the Trustee judges to be both immaterial and not rendering any prior disclosure inaccurate. No developments that occurred on or after May 15, 2026 were evaluated for inclusion or are included below.

McKinsey Litigation (*McKinsey, et al.*)

The Trust and McKinsey continue to be engaged in discovery, pursuant to the agreed Court scheduling order. Of note, recently, Purdue Pharma announced and received approval of a settlement with McKinsey, with a "headline" value of \$125 million. There are material factual and legal similarities in Purdue with the Trustee's case against McKinsey. The Trustee, cautions, however, that there are significant differences between the cases, including the causes of action surviving the Bankruptcy Court's decision on the motion to dismiss (as discussed above), those that could potentially be revived on appeal, McKinsey's defenses to each category of claims, and key differences in timing and procedural posture between the two matters.

Product Liability Insurance Coverage Litigation (*ACE Property and Casualty Insurance Company, et al.*)

The Trustee and certain defendants engaged in confidential settlement negotiations and

mediations.

Directors and Officers Litigation (*De Silva, et al.*)

On May 14, 2026, the Bankruptcy Court *sua sponte* issued an order directing the parties to submit briefing regarding the status of the action. The order suggested that the Bankruptcy Court had deferred ruling on the defendants' motions to dismiss pending the decision of the SDNY District Court on the defendants' motion to withdraw the reference of the proceeding from the Bankruptcy Court.

Litigation Settlements

Certain litigation settlement activity occurred, the details of which are not presently disclosable.

Change of Trustee's and Trust's Address

Effective April 27, 2026, the Trust and Trustee relocated their premises to c/o Dundon Advisers LLC, 575 Fifth Avenue, 16th Floor, New York NY 10017, and changed their telephone number to (212) 859-2000.